The kappa-opioid receptor: evidence for the different subtypes

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Classification of kappa-opioid receptor ligands is complex due to overlapping sigma and non-opioid activities.
• Some benzomorphans with kappa-agonistic properties also exhibit mu-antagonist effects, complicating receptor categorization.
• Existing classifications are limited to two subclasses with physiological relevance.

Purpose of the Study:

• To review the current understanding of kappa-opioid receptor classification.
• To identify proposed endogenous peptide ligands for kappa-receptors.
• To highlight the need for selective nonpeptide ligands, particularly for the kappa2 receptor subtype.

Main Methods:

• Literature review of studies on kappa-opioid receptor ligands.
• Analysis of drug-receptor interactions, including agonistic and antagonistic properties.
• Discussion of proposed endogenous ligands and existing nonpeptide agonists/antagonists.

Main Results:

• Dynorphin and Met-enkephalin-Arg6-Phe7 are proposed as endogenous kappa-receptor ligands.
• Benzeneacetamides are identified as kappa1-selective nonpeptide agonists.
• Benzomorphans interact with both kappa receptor subtypes, and Nor-binaltorphimine is a non-selective kappa antagonist.

Conclusions:

• Further research is required to develop selective kappa2 receptor ligands for precise distinction between receptor subtypes.
• Molecular cloning of opioid receptors and their subtypes is anticipated to provide definitive evidence for their existence.
• The development of selective kappa2 ligands is crucial for advancing our understanding and therapeutic targeting of kappa-opioid receptors.